Viracta Therapeutics shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $5 to $3.
Portfolio Pulse from Benzinga Newsdesk
Viracta Therapeutics shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $5 to $3.
August 16, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viracta Therapeutics shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $5 to $3.
The downgrade from Leerink Partners and the significant reduction in the price target are likely to negatively impact investor sentiment and lead to a short-term decline in Viracta Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100